Contents
Editor’s Letter
Latest features in GaBI Journal, 2012, issue 3-4
Letters to the Editor
A bioethicist’s view of the use of biosimilars
A clinician’s view of the ethics of the use of biosimilars
Editorial
Generics policies–a globally-relevant implementation challenge
Reference price systems: stakeholder dialogue and involvement
Commentary
Statin generics: no differences in efficacy after switching
Pharmacovigilance of biosimilars: challenges and possible solutions
Original Research
Saving money in the European healthcare systems with biosimilars
Review Article
Reference pricing systems in Europe: characteristics and consequences
Perspective
Terminology for biosimilars–a confusing minefield
Health professionals in the risk communication process on counterfeit medicines
Special Report
The MEDICRIME Convention: criminalising the falsification of medicines and similar crimes
Guidelines
Conference Report
The potential of generics policies: more room for exploitation–PPRI Conference Report
News
Austria could save Euros 256 million by using more generics
Abstracted Scientific Content
The potential for doctors to contribute to biosimilar guidelines